Journal article
Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study
J Curcic, A Schwizer, E Kaufman, Z Forras-Kaufman, S Banerjee, A Pal, GS Hebbard, P Boesiger, M Fried, A Steingoetter, W Schwizer, M Fox
Alimentary Pharmacology & Therapeutics | WILEY-BLACKWELL | Published : 2014
DOI: 10.1111/apt.12956
Abstract
BACKGROUND: The mechanism of reflux protection may involve a 'flap valve' at the oesophago-gastric junction (OGJ). AIM: To assess the effects of baclofen, a gamma-aminobutyric acid receptor type-B (GABA-B) agonist known to suppress reflux events, on the 'functional anatomy' of the OGJ and proximal stomach after a large test meal. METHODS: Twelve healthy volunteers (HVs) and 12 patients with gastro-oesophageal reflux disease (GERD); with erosive oesophagitis or pathological oesophageal acid exposure completed a randomised, double-blind, cross-over study. On 2 test days participants received 40-mg baclofen or placebo before ingestion of a large test meal. OGJ structure and function were assess..
View full abstractGrants
Funding Acknowledgements
This research was supported by an unrestricted grant for independent, investigator led research from Astra Zeneca Research & Development, Molndal, Sweden. Additional support was secured from the Baugarten Foundation, University of Zurich, Zurich, Switzerland and the Zurich Centre for Integrative Human Physiology (ZIHP). Mark Fox, Michael Fried and Werner Schwizer have received funds for research from Nestle Research International, AstraZeneca R&D, Given Imaging, and Reckitt Benckiser. Mark Fox has received support for educational events from Given Imaging, Medical Measurement Systems and Sandhill Scientific Instruments. He has received honoraria for presentations and/or reimbursement for attending symposia and/or is a member of advisory boards for Given Imaging, AstraZeneca, Reckitt Benckiser, Shire, Almirall and Sucampo. Other authors have no conflicts of interest to disclose.